FHTX Foghorn Therapeutics Inc.
8-K Current Report
Filed: March 11, 2026
Health Care
Pharmaceutical PreparationsFoghorn Therapeutics Inc. (FHTX) 8-K current report filed with SEC EDGAR on March 11, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.
Reported 8-K Items2 items
- Item 2.02: Results of Operations and Financial Condition
- Item 7.01: Regulation FD Disclosure
AI Filing Analysis8-K
Item 2.02 · Results of Operations and Financial Condition
- • Full-year 2025 financial results announced March 11, 2026 — details in Exhibit 99.1 press release
- • FHTX is a clinical-stage biotech; cash runway and R&D spend are key metrics to watch in the release
Item 7.01 · Regulation FD Disclosure
- • Foghorn Therapeutics (FHTX) releasing updated investor presentation dated March 2026 for use in investor meetings
- • Reg FD disclosure ensures all investors receive simultaneous access to material information shared in these meetings
Other Foghorn Therapeutics Inc. 8-K Filings
Get deeper insights on Foghorn Therapeutics Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.